Skadden, Arps, Slate, Meagher & Flom LLP has advised Lyell Immunotherapy, Inc. Lyell Immunopharma, Inc. has acquired exclusive global rights, outside of mainland China, Hong Kong,...
Lyell Immunopharma Secures Global Rights to CAR T-Cell Candidate for Metastatic Colorectal Cancer
Lyell Immunopharma’s Acquistion of ImmPACT Bio USA
Skadden, Arps, Slate, Meagher & Flom LLP is advising Lyell Immunopharma, Inc., while Cooley LLP is advising ImmPACT Bio USA Inc. on the deal. Lyell Immunopharma,...
Lyell Immunopharma’s $425 Million Initial Pubic Offering
Latham & Watkins Advises the Underwriters in the offering while Cooley LLP represented Lyell Immunopharma. Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company...